Protocol Ledger

NCT07197307 · Phase II · RECRUITING

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Interventional Phase II clinical trial protocol NCT07197307 sponsored by Universität Münster in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-31 Enrollment: 120 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07197307
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)120 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07197307
Protocol FieldVerified Registry Value
NCT IdentifierNCT07197307
Consolidated Lead SponsorUniversität Münster
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment120 participants (ESTIMATED)
Registered Start Date2025-10-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07197307
Hospital Research SiteLocationSite Profile
Universitaetsklinikum EssenEssen, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI